Biopharmaceutical News and Research

RSS

Novoheart collaborates with AstraZeneca to develop world’s first human heart-in-a-jar model of heart failure

Novoheart, a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.

26 Nov 2019

New partnership aims to explore, cultivate innovations in cell and gene therapy

Some patients who have not responded to traditional medicines are now experiencing remarkable recoveries thanks to next-generation immunotherapies. These therapies equip a patient's own immune cells to recognize, target, and destroy cancer cells.

25 Nov 2019

PhoreMost and Sentinel Oncology expand partnership to advance novel allosteric PLK1 inhibitor

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.

From PhoreMost 15 Nov 2019

Lonza launches new basal and feed medium to optimize protein production

Lonza has further expanded its cell culture media portfolio with the addition of the eCHO Basal Medium and Feed, which has been designed to optimize protein production by delivering a consistent yield and highly viable cells while keeping lactate levels to a minimum for optimal protein integrity.

From Lonza 14 Nov 2019

Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences

Cytel Inc., the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics capabilities.

From Cytel 8 Nov 2019

Researchers reveal initial results from a study of hypertrophic cardiomyopathy

Researchers have revealed the initial results from the world's largest comprehensive study of hypertrophic cardiomyopathy, an abnormal thickening of the heart that often goes undiagnosed and can prove deadly. The condition can present at any age, and it is the most common cause of sudden cardiac death in young athletes.

7 Nov 2019

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics and Peak Analysis and Automation, announce optimization of the Single Cell Analysis System through integration with automated plate handler.

From Fluidic Sciences and Sphere Bio 7 Nov 2019

Panelists explore the issue of drug pricing at ISPOR Europe 2019

ISPOR, the professional society for health economics and outcomes research - explored the issue of drug pricing in the session, "Time for Change? Has the Time Come for the Pharma Industry to Accept Modest Prices?" [IP4].

5 Nov 2019

RCSB Protein Data Bank at Rutgers receives $34.5 million funding

The RCSB Protein Data Bank headquartered at Rutgers University-New Brunswick has been awarded $34.5 million in grants over five years from three U.S. government agencies.

4 Nov 2019

Congressional briefing on moving away from dog studies in the development of new medicines

At a congressional briefing Tuesday, Vanda Pharmaceuticals, the Physicians Committee for Responsible Medicine, and the Humane Society of the United States urged Congress to task the U.S. Food and Drug Administration with moving away from dog studies and other animal testing in the development of new medicines.

30 Oct 2019

SLU research halts toxic protein linked to muscular dystrophy in animal models

There is no cure or treatment for facioscapulohumeral muscular dystrophy, an illness that starts with facial, shoulder and upper arm weakness and eventually affects nearly all skeletal muscles of those with the disease.

23 Oct 2019

Sartorius Stedim Biotech introduces Sartocheck 5 Plus filter integrity tester

Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industry, has announced the launch of its new Sartocheck 5 Plus filter integrity tester. Designed for use in downstream processing, this new integrity tester is the latest development in the established line of Sartocheck units already recognized throughout the pharmaceutical industry.

From Sartorius 23 Oct 2019

SciLifeLab and AstraZeneca establish cryo-EM collaboration to advance biomedicine

The study published in Science Advances reveals the mechanism by which the receptor tyrosine kinase RET can increase neuronal survival in degenerative diseases. To understand the mechanism of this signaling complex, the researchers solved the cryo-EM structure of its extracellular region, employing a new approach for data collection.

21 Oct 2019

Fitbit and Bristol-Myers Squibb-Pfizer Alliance team up to address gaps in atrial fibrillation

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit today announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.

17 Oct 2019

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

Sphere Fluidics, and Peak Analysis and Automation, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.

From Fluidic Sciences and Sphere Bio 16 Oct 2019

Health care market fails to support new antibiotics against superbugs, study finds

The health care market is failing to support new antibiotics used to treat some of the world's most dangerous, drug-resistant "superbugs," according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.

8 Oct 2019

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

3 Oct 2019

Novel gene therapy for glycogen storage disease shows positive results

At the Association for Glycogen Storage Disease's 41st Annual Conference, Dr. David Weinstein of UConn School of Medicine and Connecticut Children's presented his groundbreaking, one-year clinical trial results for the novel gene therapy treatment for glycogen storage disease.

20 Sep 2019

Discovery of combination protein leads to first-in-human clinical trial for leukemia

The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia.